What is the mechanism of action of this treatment?

Common treatments for Long-COVID often target oxidative stress and inflammation, which are key contributors to the condition's persistent symptoms. Rehabilitation therapies, such as structured physical exercise and respiratory rehabilitation, aim to enhance vascular endothelial function by reducing oxidative stress and inflammation. These therapies help improve blood flow, reduce fatigue, and enhance overall physical function, which are critical for Long-COVID patients experiencing prolonged symptoms like dyspnea and fatigue. By addressing these underlying mechanisms, these treatments can significantly improve the quality of life and functional status of Long-COVID patients.

What side effects are associated with this type of intervention?

Common treatments for Long-COVID that aim to improve vascular endothelial function and combat oxidative stress and inflammation include antioxidants, anti-inflammatory agents, and physical rehabilitation exercises. Antioxidants and anti-inflammatory agents can sometimes cause gastrointestinal discomfort, headaches, and allergic reactions. Physical rehabilitation exercises, while generally safe, may lead to muscle soreness, fatigue, and, in rare cases, injury if not properly supervised. Overall, these treatments are well-tolerated, but patients should be monitored for any adverse effects.

What prior FDA approvals exist?

As of now, there are no specific FDA-approved treatments for Long-COVID that directly target oxidative stress and inflammation to improve vascular endothelial function. Current research is focused on developing rehabilitation therapies to address these issues, but further studies and clinical trials are needed to establish effective treatments. Patients are advised to consult with their healthcare providers for personalized management plans.

What other types of research exist?

Promising novel alternatives to rehabilitation therapies for Long-COVID patients in 2024 include the use of inhaled nitric oxide (NO) to improve endothelial function and reduce inflammation, and the identification and targeting of specific biomarkers for endothelial health. Additionally, inhaled glucocorticoids like ciclesonide have shown potential in clinical trials and may offer benefits in managing oxidative stress and inflammation associated with Long-COVID.

← Back to Search

Mitochondrial Targeted Antioxidant

Mitoquinone for Long-COVID

N/A

Recruiting

Led By Joel Douglas Trinity, PhD

Research Sponsored by VA Office of Research and Development

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

50 years of age or greater

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline, months 3 and 6, and every 6 months thereafter until the end of year 4.

Awards & highlights

Study Summary

This trial will focus on improving the health of older Veterans and those recovering from COVID-19 by developing rehabilitation therapies to improve vascular endothelial function.

Who is the study for?

This trial is for veterans and others aged 50 or older who are recovering from COVID-19, specifically those with Long-COVID symptoms 3-12 months after diagnosis. Participants must be able to consent and have a confirmed SARS-CoV-2 test at the time of their initial illness. People with severe heart disease, uncontrolled high blood pressure, extreme obesity, recent smokers, or certain chronic diseases cannot join.Check my eligibility

What is being tested?

The study tests Mitoquinone (a supplement aimed at reducing oxidative stress) against a placebo in improving vascular function post-COVID. It aims to develop therapies that help rehabilitation by addressing long-term effects of COVID on the body's blood vessels.See study design

What are the potential side effects?

While specific side effects are not listed here, Mitoquinone may cause similar reactions as other supplements targeting oxidative stress such as digestive discomfort or allergic reactions; placebos typically have no active ingredients but can lead to perceived side effects.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 50 years old or older.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline, months 3 and 6, and every 6 months thereafter until the end of year 4.

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline, months 3 and 6, and every 6 months thereafter until the end of year 4.

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, months 3 and 6, and every 6 months thereafter until the end of year 4. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Respiration

Change in Flow Mediated Dilation (FMD)

Leg

Trial Design

2Treatment groups

Experimental Treatment

Placebo Group

Group I: Exercise RehabilitationExperimental Treatment2 Interventions

Participants will be assigned to the Exercise+Placebo or Exercise+Mito-Q rehabilitation interventions using block randomization (block size 10).

Group II: Exercise Rehabilitation with PlaceboPlacebo Group2 Interventions

Participants will be assigned to Exercise+Placebo rehabilitation using block randomization (block size 10)

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Placebo

1995

Completed Phase 3

~2670

0 / 1Eligibility criteria met

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.

Mechanism Of Action

Side Effect Profile

Prior Approvals

Other Research

Common treatments for Long-COVID often target oxidative stress and inflammation, which are key contributors to the condition's persistent symptoms. Rehabilitation therapies, such as structured physical exercise and respiratory rehabilitation, aim to enhance vascular endothelial function by reducing oxidative stress and inflammation. These therapies help improve blood flow, reduce fatigue, and enhance overall physical function, which are critical for Long-COVID patients experiencing prolonged symptoms like dyspnea and fatigue. By addressing these underlying mechanisms, these treatments can significantly improve the quality of life and functional status of Long-COVID patients.

Pulmonary vasodilators: beyond the bounds of pulmonary arterial hypertension therapy in COVID-19.